# Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

> **NCT02201992** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 166 (actual)

## Conditions studied

- ALK Gene Rearrangement
- ALK Gene Translocation
- ALK Positive
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **OTHER:** Clinical Observation
- **DRUG:** Crizotinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02201992
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-03-23
- **Primary completion:** 2036-05-01
- **Final completion:** 2036-05-01
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201992, "Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02201992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*